Abstract

Onychomycosis affects around one-half of all nail disease and one-third of integumentary fungal infections. The term “onychomycosis” is derived from the Greek words “onyx” means nail and “mykes” means fungus. Onychomycosis is mostly caused by dermatophytes, although Candida species and nondermatophyte molds may also cause disease. It is a stimulating nail condition to treat. Onychomycosis may have significant psychosocial effects, and negatively impacting quality of life.  Fungal pathogens disrupt the integrity of the skin by means of scaling and fissure formation. These pathogens typically start by penetrating at the distal end of the nail bed, causing distal subungual onychomycosis, which is the most common form of fungal nail disease. Less frequently, infection at the surface of the nail plate can lead to white superficial onychomycosis; invasion near the cuticle can result in proximal subungual onychomycosis; and candidal infections of the nail can occur in case of human immunodeficiency virus and decreased immunity.

Case 

We present herewith a case of a 32-year-old man with a red scaly rash and nail dystrophy. A fungal culture of a nail clipping grew out M gypseum, and the patient was treated with Luliconazole daily for  1 week for dystrophic onychomycosis and tinea corporis. After the 1 week of treatment, the erythema at the proximal nail fold and distal finger had improved but still persisted. An additional 1 weeksof daily treatment completely resolved the clinical manifestations of onychomycosis.

Conclusion

Onychomycosis affects 10% to 12% of populationworldwide. Luliconazole cream 1% is a broad-spectrum, imidazole antimycotic agent. Luliconazole cream 1% is safe and well tolerated when administered once daily for 14 days. Studies pertaining to onychomycosis used solutions of 1% applied daily for 2 weeks and assessed outcomes at the end of the treatment course; at this concentration, randomized control studies showed similar efficacy for Luliconazole. 

Suggested Reading

1. Leung AKC, Lam JM, Leong KF, et al. Onychomycosis: An Updated Review. Recent Patents on Inflammation & Allergy Drug Discovery. 2020;14(1):32-45. DOI: 10.2174/1872213x13666191026090713.
2. Fike J.M., Kollipara R., Alkul S., Stetson C.L. Case report of onychomycosis and tinea corporis due to Microsporumgypseum. J. Cutan. Med. Surg. 2018;22(1):94–96. doi: 10.1177/1203475417724439.
3. Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol. 2009;47:640–647.
4. Watanabe S, Kishida H, Okubo A. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2017 Jul;44(7):753-759. doi: 10.1111/1346-8138.13816. Epub 2017 Mar 23. PMID: 28332720.